Merck's Q3 2022 earnings call highlighted strong performance, particularly in KEYTRUDA, GARDASIL, and Animal Health.  Management expressed confidence in the pipeline, with positive data from the STELLAR trial for sotatercept.  However, the call also mentioned temporary challenges with CDC purchase timing for GARDASIL and foreign exchange headwinds, potentially impacting short-term stock price movements.
[1]
